| 1 |
Li X, Zhou L, Gaggl M, Kinlaw AC, Gou Z, Xu Y, Wei J, Wang T. Remdesivir for COVID-19 and acute kidney injury: disproportionality analysis of data from the U.S. Food and Drug Administration Adverse Event Reporting System. Int J Clin Pharm 2023. [PMID: 36964312 DOI: 10.1007/s11096-023-01554-4] [Reference Citation Analysis]
|
| 2 |
Ayyashi M, Darbashi H, Hakami A, Sharahili F. Evaluation of Remdesivir Utilization Pattern in Critically Ill Patients With COVID-19 in Jazan Province. Cureus 2023. [DOI: 10.7759/cureus.36247] [Reference Citation Analysis]
|
| 3 |
Parchwani D, Sonagra AD, Dholariya S, Motiani A, Singh R. COVID-19-related liver injury: Focus on genetic and drug-induced perspectives. World J Virol 2023; 12(1): 53-67 [DOI: 10.5501/wjv.v12.i1.53] [Reference Citation Analysis]
|
| 4 |
Wang Z, Yang L, Song XQ. Oral GS-441524 derivatives: Next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase. Front Immunol 2022;13:1015355. [PMID: 36561747 DOI: 10.3389/fimmu.2022.1015355] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 5 |
Jansen-van Vuuren RD, Jedlovčnik L, Košmrlj J, Massey TE, Derdau V. Deuterated Drugs and Biomarkers in the COVID-19 Pandemic. ACS Omega 2022. [DOI: 10.1021/acsomega.2c04160] [Reference Citation Analysis]
|
| 6 |
Wong CKH, Au ICH, Cheng WY, Man KKC, Lau KTK, Mak LY, Lui SL, Chung MSH, Xiong X, Lau EHY, Cowling BJ. Editorial: liver and kidney injury from remdesivir-an issue not as much as its purpose. Authors' reply. Aliment Pharmacol Ther 2022;55:1457-8. [PMID: 35538354 DOI: 10.1111/apt.16932] [Reference Citation Analysis]
|
| 7 |
Vuppalanchi S, Vuppalanchi R. Editorial: liver and kidney injury from remdesivir-an issue not as much as its purpose. Aliment Pharmacol Ther 2022;55:1456. [PMID: 35538355 DOI: 10.1111/apt.16921] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Wong CKH, Lau KTK, Au ICH, Xiong X, Chung MSH, Leung BYC, Lau EHY, Cowling BJ. Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone. Front Pharmacol 2022;13:866441. [DOI: 10.3389/fphar.2022.866441] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 9 |
. Remdesivir does not increase risk of AKI or ALI in COVID-19 patients. Reactions Weekly 2022;1901:12-12. [DOI: 10.1007/s40278-022-12689-0] [Reference Citation Analysis]
|
| 10 |
Wong CKH, Low MCH, Kwok ACY, Lui AYC, Lau KTK, Au ICH, Xiong X, Chung MSH, Kwan MYW, Lau EHY, Cowling BJ. Slower Recovery with Early Lopinavir/Ritonavir use in Pediatric COVID-19 Patients: A Retrospective Observational Study. Paediatr Drugs 2022;24:269-80. [PMID: 35428969 DOI: 10.1007/s40272-022-00500-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
